News for ImmunoGen, Inc. (IMGN)

Michael Vasconcelles, M.D., joins Day One Biopharmaceuticals (DAWN) as Head of Research & Development. Dr. Vasconcelles brings over 25 years of experien

This could upend an already shaky stock market. The recent market downturn is an excellent example. After the election, the general consensus was that the new administration would be positive for the stock market, and the major indexes rose immediately after Election Day.

PR NewswireTOKYO, May 7, 2025 TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today annou

**media[614529]**

**media[559681]**

AbbVie cuts 2024 profit forecast on acquisition expenses

PESG Research Releases an Market Update Report on [url="]Silexion Therapeutics (NASDAQ: SLXN)[/url]. The precision oncology sector has rapidly evolved into one

SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. ( CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial O

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer

These stocks trade at less than 20 times their estimated future profits.

These companies can lend growth and dividend returns to a long-term investor's portfolio.

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and was the top-selling ADC globally in 2023

Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 β/γ in combination with...

Advancements and Projections in the Antibody Drug Conjugates Market: Insights, Trends, Opportunities, and Recent Developments...

The IDH inhibitors market is expected to grow significantly in the coming years. This is due to the rising occurrence of IDH-mutated cancers, such as acute...

Cerevel Therapeutics presents a potential arbitrage opportunity with its acquisition by AbbVie, offering over 10% returns for investors. Read more on CERE stock.

Insights from Maverick Capital's Latest 13F Filing

Insights from Maverick Capital's Latest 13F Filing Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, has once again made notable change